Ryan Specialty (RYAN) news
Recent news
Biocon's Shaw: Biosimilars a very attractive segment
Biocon, India’s largest biopharmaceutical company, has positioned itself as a key player in the global biosimilars market, with its chairman and managing director, Kiran Mazumdar-Shaw, emphasizing the segment’s growing potential. The company recently received approval for its Glargine biosimilar in…
AInvest Wire · 2d agoRyan Specialty Holdings, Inc.: Wells Fargo cuts target price to $41 from $43
AInvest Wire · 3d agoRyan Specialty Holdings, Inc.: KBW cuts target price to $49 from $54
KBW has revised its price target for Ryan Specialty Holdings, Inc. (RYAN), reducing it to $49 from a previous estimate of $54. The adjustment reflects updated analyst assessments of the company’s performance and market positioning. Ryan Specialty, which operates in the insurance brokerage,…
AInvest Wire · 3d agoRyan Specialty Holdings, Inc.: Piper Sandler cuts target price to $40 from $48
AInvest Wire · Oct 6, 2026Moody’s Ratings affirms Ryan Specialty’s BA3 corporate family rating; outlook stable
AInvest Wire · Aug 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.